259537-92-3 Usage
Description
(R)-2-(Aminomethyl)-1-N-Boc-pyrrolidine is a chiral, synthetic organic compound characterized by its specific (R)-configuration and the presence of an aminomethyl group and a Boc-protected pyrrolidine ring. (R)-2-(Aminomethyl)-1-N-Boc-pyyrolidine is significant in the field of organic chemistry and pharmaceuticals due to its potential applications in the synthesis of various biologically active molecules.
Uses
Used in Pharmaceutical Industry:
(R)-2-(Aminomethyl)-1-N-Boc-pyrrolidine is used as a key intermediate in the synthesis of various pharmaceutical compounds, particularly those targeting the adenosine A2A receptor. Its unique structure allows for the development of potent and selective antagonists, which can be beneficial in treating a range of conditions, including neurodegenerative diseases and certain types of cancer.
Used in Chemical Synthesis:
In the field of chemical synthesis, (R)-2-(Aminomethyl)-1-N-Boc-pyrrolidine serves as a valuable reactant for the creation of diamino derivatives of [1, 2, 4] triazolo [1, 5-a][1, 3, 5] triazine. These derivatives have been identified as potent and selective adenosine A2A receptor antagonists, making them important candidates for further research and potential therapeutic applications.
Check Digit Verification of cas no
The CAS Registry Mumber 259537-92-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,5,9,5,3 and 7 respectively; the second part has 2 digits, 9 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 259537-92:
(8*2)+(7*5)+(6*9)+(5*5)+(4*3)+(3*7)+(2*9)+(1*2)=183
183 % 10 = 3
So 259537-92-3 is a valid CAS Registry Number.
259537-92-3Relevant articles and documents
INHIBITORS OF HUMAN TUMOR-EXPRESSED CCXCKR2
-
Page 57-58, (2008/06/13)
Pharmaceutical compositions containing organic compounds or salts thereof that serve as modulators for the SDF-1 or I-TAC chemokines are disclosed. The compounds and compositions are useful in the treatment of cancer, especially in the inhibition of cancer proliferation, growth, and metastasis. Methods of interfering with SDF-1 and/or I-TAC binding to the CCXCKR2 receptor and treating cancer using the compounds and pharmaceutical compositions of the present invention are also disclosed.
Synthesis and hybridization of novel chiral pyrrolidine based PNA analogue
Slaitas,Yeheskiely
, p. 1377 - 1379 (2007/10/03)
Four different PNA fragments containing units of either the R- or S- isomer of N-(2-pyrrolidine-methyl)-N-(thymine-1-acetyl)-glycine (Pmg) were synthesized on a solid support. UV thermal melting experiments with complementary RNAs were performed and it was found that R-Pmg containing PNAs bind better to RNA than those containing the S-Pmg units.
Antithrombotic agents
-
, (2008/06/13)
Compounds of formula (I) : are antithrombotic agents, having utility in a variety of therapeutic areas including the prevention and/or treatment of deep vein thrombosis (DVT) after surgery, major medical illness, paralysis, malignancy, prolonged immobilis
